HEOR

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

NICE rejects Orchard's gene therapy for rare childhood disea...

Orchard Therapeutics' gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance.

News

MHRA grants bluebird 'innovation passport' for sickle cell t...

bluebird bio's sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an 'innovation passport' introduced in the UK earlier this year to speed up NHS access to promisi

News

Red spine and vertebral column of a human skeleton

NICE backs Novartis' Cosentyx for underdiagnosed back condit...

NICE has extended the range of indications that Novartis' Cosentyx can be prescribed for by the NHS in England, giving a green light for its use in non-radiographic axial spondyloarthritis

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

NICE 'no' to Roche's risdiplam for SMA not unexpected, says ...

NICE has rejected routine NHS funding for Roche's Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn't come as a surprise to patient association

News

Scotland backs NHS use of Alexion's Ultomiris for rare disea...

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion's Ultomiris, ahead of their counterparts in Engla

News

NICE says no to Merck Serono's Bavencio in bladder cancer

Merck Serono's Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE says it is to

NICE rejects Orchard's gene therapy for rare childhood disea...

MHRA grants bluebird 'innovation passport' for sickle cell t...

NICE backs Novartis' Cosentyx for underdiagnosed back condit...

NICE 'no' to Roche's risdiplam for SMA not unexpected, says ...

Scotland backs NHS use of Alexion's Ultomiris for rare disea...

NICE says no to Merck Serono's Bavencio in bladder cancer

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

HEOR

Editor's Picks